Acorda Therapeutics reports FDA issues CRL for Plumiaz Acorda Therapeutics announced that the FDA has issued a Complete Response Letter, or CRL, for the New Drug Application for Plumiaz Nasal Spray for the treatment of people with epilepsy who experience cluster seizures. A CRL is a communication from the FDA that informs a company that their review of the NDA is complete and the application cannot be approved in its present form. The company is currently developing a response to address the items outlined in the letter.
News For ACOR From The Last 14 Days
Check below for free stories on ACOR the last two weeks.